混合性心脏性休克与败血症中的内诺特洛普选择:米利诺和多布他胺之间的比较分析
Boyangzi Li1, Hayley B Gershengorn2,3, Emily A Vail4
1University of Minnesota Medical School - Twin Cities Campus, Cardiovascular Division, Department of Medicine, Minneapolis, Minnesota, United States; li003977@umn.edu.
Annals of the American Thoracic Society
|September 17, 2025
概括
在患有心脏性休克和败血症的患者中,多布他和米利诺显示出类似的住院死亡率. 然而,与milrinone相比,dobutamine与较短的治疗持续时间和住院时间有关.
科学领域:
- 心脏病学 心脏病学
- 关键护理医学 关键护理医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 混合心脏性休克,特别是血症,会给治疗带来挑战.
- 在这种复杂的患者群体中,最佳的内类药物选择仍然不清楚.
研究的目的:
- 为了比较dobutamine与milrinone在患有同时心脏性休克和败血症的患者中的有效性.
- 检查异能选择与住院结果 (包括死亡率) 之间的关联.
主要方法:
- 从PINC AI增强索赔数据库 (2016-2022) 中对10,447名患者进行了回顾性分析.
- 使用心脏病性休克和败血症的ICD-10代码识别的患者,在入院后2天内使用多布他或米利诺.
- 一般化完全匹配和g计算用于分析诸如死亡率,内持续时间,停留时间和不良事件等结果.
主要成果:
- 在milrinone和dobutamine组 (41.6%和42.7%) 之间,在全因住院死亡率上没有显著差异.
- 米利诺的使用与更长的内持续时间 (5.1 vs 3.5 天),更长的住院时间 (10.0 vs 9.1 天) 和增加抗心律失常剂的使用有关.
- 根据先前存在的疾病,没有观察到治疗对死亡率的影响异质性.
结论:
- 多布他胺和米利诺恩在患有心脏病性休克和败血症的患者的住院死亡率相似.
- 由于治疗时间较短和住院时间较长,多布他胺似乎更受欢迎.
- 进一步的研究可能会探索特定的患者亚组,其中一个药物可能提供优势.
相关概念视频
Heart Failure Drugs: Inotropic Agents
1.3K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.3K
Heart Failure Drugs: β-Blockers
772
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
772
Heart Failure V: Medical Management
223
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
223
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
942
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
942
Cardiomyopathy II: Dilated Cardiomyopathy
480
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
480
Cardiopulmonary Resuscitation IV: Pharmacological Management
675
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
675


